118 related articles for article (PubMed ID: 38052369)
41. Tumor-associated macrophages promote epithelial-mesenchymal transition and the cancer stem cell properties in triple-negative breast cancer through CCL2/AKT/β-catenin signaling.
Chen X; Yang M; Yin J; Li P; Zeng S; Zheng G; He Z; Liu H; Wang Q; Zhang F; Chen D
Cell Commun Signal; 2022 Jun; 20(1):92. PubMed ID: 35715860
[TBL] [Abstract][Full Text] [Related]
42. SHP2 Potentiates the Oncogenic Activity of β-Catenin to Promote Triple-Negative Breast Cancer.
Martin E; Agazie YM
Mol Cancer Res; 2021 Nov; 19(11):1946-1956. PubMed ID: 34389690
[TBL] [Abstract][Full Text] [Related]
43. In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis.
Li Y; Xiao Y; Lin HP; Reichel D; Bae Y; Lee EY; Jiang Y; Huang X; Yang C; Wang Z
Biomaterials; 2019 Jan; 188():160-172. PubMed ID: 30352320
[TBL] [Abstract][Full Text] [Related]
44. Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP).
Qian XL; Zhang J; Li PZ; Lang RG; Li WD; Sun H; Liu FF; Guo XJ; Gu F; Fu L
PLoS One; 2017; 12(1):e0171169. PubMed ID: 28141839
[TBL] [Abstract][Full Text] [Related]
45. Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling.
Chen Y; Chen ZY; Chen L; Zhang JY; Fu LY; Tao L; Zhang Y; Hu XX; Shen XC
Biochem Pharmacol; 2019 Aug; 166():33-45. PubMed ID: 31071331
[TBL] [Abstract][Full Text] [Related]
46. Diallyl disulfide inhibits growth and metastatic potential of human triple-negative breast cancer cells through inactivation of the β-catenin signaling pathway.
Huang J; Yang B; Xiang T; Peng W; Qiu Z; Wan J; Zhang L; Li H; Li H; Ren G
Mol Nutr Food Res; 2015 Jun; 59(6):1063-75. PubMed ID: 25755089
[TBL] [Abstract][Full Text] [Related]
47. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells.
Bilir B; Kucuk O; Moreno CS
J Transl Med; 2013 Nov; 11():280. PubMed ID: 24188694
[TBL] [Abstract][Full Text] [Related]
48. Reduced lncRNA Aim enhances the malignant invasion of triple-negative breast cancer cells mainly by activating Wnt/β-catenin/mTOR/PI3K signaling.
Liu L; Yu D; Shi H; Li J; Meng L
Pharmazie; 2017 Oct; 72(10):599-603. PubMed ID: 29441885
[TBL] [Abstract][Full Text] [Related]
49. Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer.
Lin CC; Lo MC; Moody R; Jiang H; Harouaka R; Stevers N; Tinsley S; Gasparyan M; Wicha M; Sun D
Cancer Lett; 2018 Dec; 438():165-173. PubMed ID: 30227220
[TBL] [Abstract][Full Text] [Related]
50. A novel humanized Frizzled-7-targeting antibody enhances antitumor effects of Bevacizumab against triple-negative breast cancer via blocking Wnt/β-catenin signaling pathway.
Xie W; Zhao H; Wang F; Wang Y; He Y; Wang T; Zhang K; Yang H; Zhou Z; Shi H; Wang J; Huang G
J Exp Clin Cancer Res; 2021 Jan; 40(1):30. PubMed ID: 33436039
[TBL] [Abstract][Full Text] [Related]
51. Canonical Wnt signaling induces vascular endothelial dysfunction via p66Shc-regulated reactive oxygen species.
Vikram A; Kim YR; Kumar S; Naqvi A; Hoffman TA; Kumar A; Miller FJ; Kim CS; Irani K
Arterioscler Thromb Vasc Biol; 2014 Oct; 34(10):2301-9. PubMed ID: 25147340
[TBL] [Abstract][Full Text] [Related]
52. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.
Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X
J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797
[TBL] [Abstract][Full Text] [Related]
53. Tweaking EMT and MDR dynamics to constrain triple-negative breast cancer invasiveness by EGFR and Wnt/β-catenin signaling regulation.
Shome R; Ghosh SS
Cell Oncol (Dordr); 2021 Apr; 44(2):405-422. PubMed ID: 33398673
[TBL] [Abstract][Full Text] [Related]
54. Downregulation of beta-catenin in chemo-tolerant TNBC through changes in receptor and antagonist profiles of the WNT pathway: Clinical and prognostic implications.
Islam S; Dasgupta H; Basu M; Roy A; Alam N; Roychoudhury S; Panda CK
Cell Oncol (Dordr); 2020 Aug; 43(4):725-741. PubMed ID: 32430683
[TBL] [Abstract][Full Text] [Related]
55. MicroRNA-124-3p.1 promotes cell proliferation through Axin1-dependent Wnt signaling pathway and predicts a poor prognosis of triple-negative breast cancer.
Yang W; Cui G; Ding M; Yang M; Dai D
J Clin Lab Anal; 2020 Jul; 34(7):e23266. PubMed ID: 32125723
[TBL] [Abstract][Full Text] [Related]
56. DNER promotes epithelial-mesenchymal transition and prevents chemosensitivity through the Wnt/β-catenin pathway in breast cancer.
Wang Z; Li Z; Wu Q; Li C; Li J; Zhang Y; Wang C; Sun S; Sun S
Cell Death Dis; 2020 Aug; 11(8):642. PubMed ID: 32811806
[TBL] [Abstract][Full Text] [Related]
57. circ-EIF6 encodes EIF6-224aa to promote TNBC progression via stabilizing MYH9 and activating the Wnt/beta-catenin pathway.
Li Y; Wang Z; Su P; Liang Y; Li Z; Zhang H; Song X; Han D; Wang X; Liu Y; Yang J; Chen B; Wang L; Zhao W; Yang Q
Mol Ther; 2022 Jan; 30(1):415-430. PubMed ID: 34450253
[TBL] [Abstract][Full Text] [Related]
58. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
Wang DY; Gendoo DMA; Ben-David Y; Woodgett JR; Zacksenhaus E
Breast Cancer Res; 2019 Jan; 21(1):18. PubMed ID: 30704524
[TBL] [Abstract][Full Text] [Related]
59. Circ-ITCH regulates triple-negative breast cancer progression through the Wnt/β-catenin pathway.
Wang ST; Liu LB; Li XM; Wang YF; Xie PJ; Li Q; Wang R; Wei Q; Kang YH; Meng R; Feng XH
Neoplasma; 2019 Mar; 66(2):232-239. PubMed ID: 30509108
[TBL] [Abstract][Full Text] [Related]
60. Cancer‑associated fibroblast‑derived LRRC15 promotes the migration and invasion of triple‑negative breast cancer cells via Wnt/β‑catenin signalling pathway regulation.
Yang Y; Wu H; Fan S; Bi Y; Hao M; Shang J
Mol Med Rep; 2022 Jan; 25(1):. PubMed ID: 34726255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
